Company news

Novartis AG news in 2025

Novartis AG's news releases, calls and decks from 2025, newest first.

View company

Novartis and US government reach agreement on lowering drug prices in the US

December 19, 2025

Novartis breaks ground on flagship manufacturing hub in North Carolina

December 12, 2025

Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses

December 9, 2025

1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years

December 9, 2025

Relation announces strategic collaboration with Novartis to advance therapeutics for atopic diseases

December 9, 2025

Opterion Health AG Announces Appointment of Andreas Schuh as Chief Financial Officer

December 1, 2025

Novartis Canada Welcomes Dimitri Gitas as New Country President

November 25, 2025

Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS

November 25, 2025

Muscular Dystrophy Association Calls FDA Approval of Novartis’ Itvisma (onasemnogene abeparvovec-brve) a Major Step Forward for the Spinal Muscular Atrophy Community

November 24, 2025

Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)

November 24, 2025

Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets

November 20, 2025

Novartis announces plans to build flagship manufacturing hub in North Carolina

November 19, 2025

Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance

November 12, 2025

Sickle Cell Disease Treatment Market Research Report 2025 Featuring Novartis, Pfizer, Bluebird Bio, GlycoMimetics, Emmaus Medical, BMS, CRISPR Therapeutics, Graphite Bio

November 11, 2025

Novartis opens new radioligand therapy manufacturing facility in California as part of $23B US expansion plan

November 10, 2025

Monte Rosa Therapeutics Announces Third Quarter 2025 Financial Results and Business Updates

November 6, 2025

New Novartis data at ASN Kidney Week and AHA Scientific Sessions demonstrate momentum of broad CRM portfolio and pipeline

November 4, 2025

Meharry and Novartis Partner on HEART Initiative for Healthier Communities

November 3, 2025

Breckenridge announces launch of Everolimus Tablets, 1mg, generic version of Zortress®

October 30, 2025

Novartis ianalumab first drug to reduce disease activity and patient burden in Sjögren’s disease Phase III trials

October 29, 2025

Novartis completes acquisition of Tourmaline Bio

October 28, 2025

Novartis announces expiration of Tourmaline Bio tender offer

October 28, 2025

Novartis delivers solid sales and core operating income growth with strong pipeline progress in Q3; reaffirms FY 2025 guidance

October 28, 2025

CMS (867.HK; 8A8.SG) Signed A Distribution Agreement for Ophthalmic Drugs Lucentis® and Beovu®

October 27, 2025

Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience pipeline

October 26, 2025

Novartis showcases significant immunology advancements in ACR congress with new data in complex autoimmune diseases

October 25, 2025

Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR)

October 22, 2025

Novartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer

October 22, 2025

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis

October 21, 2025

PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer

October 19, 2025

Novartis Kisqali® 5-year NATALEE data demonstrate 28% reduction in risk of recurrence in the broadest early breast cancer patient population

October 17, 2025

Novartis Scemblix® receives positive CHMP opinion for the treatment of adults with newly diagnosed CML

October 17, 2025

Novartis Fabhalta® (iptacopan) meets Phase III primary endpoint, slows kidney function decline in patients with IgA nephropathy (IgAN)

October 16, 2025

NCCN Awards Funding to Improve Care for People with Breast Cancer

October 1, 2025

Novartis receives FDA approval for Rhapsido® (remibrutinib), the only oral, targeted BTKi treatment for chronic spontaneous urticaria (CSU)

September 30, 2025

Novartis to Launch Direct-to-Patient Platform for Cosentyx® (secukinumab) in the US

September 29, 2025

Novartis announces commencement of tender offer to acquire Tourmaline Bio

September 29, 2025

Novartis to showcase transformative data in advanced prostate and early breast cancer at ESMO 2025

September 26, 2025

Regenerative Medicine Industry Trends and Growth Strategies, 2025-2030 Featuring Novartis, Biogen, GlaxoSmithKline, Baxter International, and Boehringer Ingelheim

September 25, 2025

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

September 24, 2025

Monte Rosa Therapeutics Announces Collaboration with Novartis for Degraders to Treat Immune-mediated Diseases

September 15, 2025

Tourmaline Bio Enters into Agreement to be Acquired by Novartis AG

September 9, 2025

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD)

September 9, 2025

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement

September 2, 2025

Novartis Leqvio® shows statistically significant and clinically meaningful early LDL-C goal achievement with less muscle pain

August 30, 2025

Leqvio® advances toward broader access with agreement between Novartis and the pan-Canadian Pharmaceutical Alliance

August 21, 2025

New Novartis ESC data highlights strength of cardiovascular portfolio

August 18, 2025

Novartis ianalumab Phase III trial meets primary endpoint in ITP, demonstrating statistically significant improvement in time to treatment failure

August 12, 2025

Calls in 2025

Decks in 2025